



Patent Claims

1. Use of a pleuromutilin in the preparation of a medicament for the treatment of diseases caused by *Mycobacterium*.
2. A method of treating diseases mediated by *Mycobacterium*, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.
3. Use according to claim 1 or a method according to claim 2 wherein *Mycobacterium* is *Mycobacterium tuberculosis*.
4. Use or a method according to any one of the preceding claims wherein a pleuromutilin is a compound comprising the basic structural elements as set out in formula




wherein R is vinyl or ethyl and the dotted line is a bond or is no bond.


5. Use or a method according to claim 4 wherein a pleuromutilin is selected from the group consisting of
- a compound of formula




- a compound of formula



- a compound of formula




- a compound of formula




5


- a compound of formula




- a compound of formula




- a compound of formula



5 - a compound of formula




- a compound of formula



and








- a compound of




- 5 6. A compound selected from the group consisting of compounds of formulae as set out in TABLE 1:

TABLE 1

TABLE 1

	
	
	
<p>and</p>	

7. A compound of formula



wherein

- the dotted line is a bond (double bond between positions a=b), R_{1A} is hydrogen and R_{2A} is not present,

or

- 5 - the dotted line is no bond (single bond between positions a-b) and R_{1A} and R_{2A} independently of each other are hydrogen, halogen or deuterium,

R_{3A} is (C_{1-6}) alkyl,

R_{4A} is hydrogen, (C_{1-6}) alkyl, a group $-C(=NH)-NH_2$, or the residue of an amino acid,

R_{5A} is hydrogen, or


- 10 R_{4A} and R_{5A} together are a group $=CH-NH_2$,

R_{6A} is hydrogen or deuterium, and

m_A is 0, 1, 2, 3, 4, or 5.

8. A 14-O-(oximino- (C_{3-8}) cycloalkyl-sulfanylmethylcarbonyl)-pleuromutilin and a 14-O-(hydrazono- (C_{3-8}) cycloalkyl-sulfanylmethylcarbonyl)-pleuromutilin.

9. A compound of formula



wherein

- 20 R_{1B} has the meaning of R_{1A} as defined in claim 7,

R_{2B} has the meaning of R_{2A} as defined in claim 7,

R_{10B} has the meaning of R_{6A} as defined in claim 7,

the dotted line has the meaning as defined in claim 7,

m_B has the meaning of m_A as defined above,

- 25 R_{3B} is hydrogen or (C_{1-6}) alkyl,

X_B is $-O-R_{4B}$ or $-NR_{5B}R_{6B}$,


R_{4B} is hydrogen or (C_{1-6}) alkyl, optionally substituted by a group $-NR_{7B}R_{8B}$,

R_{5B} and R_{6B} independently of each other are (C_{1-4}) alkyl,

R_{7B} and R_{8B} independently of each other are (C_{1-4}) alkyl, or
 R_{7B} and R_{8B} together with the nitrogen atom to which they are attached form aliphatic heterocyclyl, having 5 to 8 ring members, and
 R_{9B} is hydrogen or (C_{1-4}) alkyl.

5

10. A compound of formula



wherein

R_{1C} has the meaning of R_{1A} as defined in claim 7,

R_{2C} has the meaning of R_{2A} as defined in claim 7,


the dotted line has the meaning as defined in claim 7,

R_{4C} has the meaning of R_{6A} as defined in claim 7, and

R_{3C} is amino, (C_{1-4}) alkylamino, di (C_{1-4}) alkylamino, the residue of an amino acid, hydroxy, or (C_{1-4}) alkoxy.

15

11. A compound of formula



wherein

R_{1D} has the meaning of R_{1A} as defined in claim 7,

R_{2D} has the meaning of R_{2A} as defined in claim 7,

R_{4D} has the meaning of R_{6A} as defined in claim 7,

the dotted line has the meaning as defined in claim 7, and

20

R_{3D} is aliphatic heterocyclyl of 4 to 8 ring members, and comprising one nitrogen atom as the heteroatom, or (C₄₋₈)cycloalkyl, which heterocyclyl or cycloalkyl is substituted by hydroxy or oxo.

- 5 12. A compound of any one of claims 7 to 11 in the form of a salt.
13. A compound of any one of claims 7 to 12 for use as a pharmaceutical.
- 10 14. A pharmaceutical composition comprising a compound of of any one of claims 7 to 12 in association with at least one pharmaceutical excipient.
- 15 15. A pharmaceutical composition according to claim 13, further comprising another pharmaceutically active agent.
- 15 16. A pharmaceutical composition comprising a pleuromutilin in association with at least one pharmaceutical excipient, and further comprising another pharmaceutically active agent useful in the treatment of Mycobacterium infections.
- 20 17. A compound of any one of claims 7 to 12, or a pharmaceutical composition of any one of claims 14 or 15 for use in the preparation of a medicament for the treatment of microbial diseases.
- 25 18. A method of treatment of microbial diseases, which method comprises administering to a subject in need of such treatment an effective amount of a compound of any one of claims 7 to 12 or a pharmaceutical composition of any one of claims 14 or 15.